Seeing Is Believing

Currently out of the existing stock ratings of Joshua Schimmer, 250 are a BUY (90.91%), 25 are a HOLD (9.09%).
Analyst Joshua Schimmer, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 62.2% that have a potential upside of 56.1% achieved within 397 days.
Joshua Schimmer’s has documented 758 price targets and ratings displayed on 61 stocks. The coverage is on Healthcare, Industrials, Technology, Energy, Consumer Defensive sectors.
Most recent stock forecast was given on NBIX, Neurocrine Biosciences at 31-Jul-2026.
Analyst best performing recommendations are on TAL (TAL EDUCATION GROUP).
The best stock recommendation documented was for CRSP (CRISPR THERAPEUTICS AG) at 11/14/2016. The price target of $21 was fulfilled within 2 days with a profit of $3.4 (19.32%) receiving and performance score of 96.59.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 28-Jul-2017
$205
$22.5 (12.33%)
Hold Since 03-May-2021
$173
$-9.5 (-5.21%)
$156
Hold Since 04-Feb-2021
$190
$7.5 (4.11%)
$190
Buy Since 06-Sep-2019
$175
$-7.5 (-4.11%)
$165
Buy Since 17-Jul-2017
$166
$-16.5 (-9.04%)
$175
Which stock is Joshua Schimmer is most bullish on?
Which stock is Joshua Schimmer is most reserved on?
What Year was the first public recommendation made by Joshua Schimmer?